Skip to main content

Table 3 Univariate analysis for OS in younger GBM patients (age < 60 yrs) of TCGA database

From: Identification of prognostic values defined by copy number variation, mRNA and protein expression of LANCL2 and EGFR in glioblastoma patients

Variable No.(%) Median OS (months) P Median PFS (months) P
Gender    0.002   0.131
 Male 78 (57.78) 15.39   7.86  
 Female 57 (42.22) 22.49   8.48  
LANCL2 gene status    0.054   0.177
 Amplification 33 (24.44) 15.02   5.85  
 No alteration 102 (75.56) 18.08   8.48  
EGFR gene status    0.128   0.795
 Amplification 56 (41.48) 17.49   8.12  
 No alteration 79 (58.52) 17.79   7.63  
LANCL2 and EGFR genes status    0.054   0.177
 Co-amplification 33 (24.44) 15.02   5.85  
 No alteration 102 (75.56) 18.08   8.48